Overview

Efficacy and Safety Study of Fluticasone Proponate Inhalation Solution in Adult and Adolescent Asthma

Status:
Completed
Trial end date:
2013-11-07
Target enrollment:
Participant gender:
Summary
This is a multicentre, randomized, single-blind, active-controlled, parallel-group phase III local registration study for a treatment period of 12 weeks. This study aims to assess the effectiveness and safety of fluticasone propionate 1mg via nebulizer BID in treatment of Chinese adult and adolescent patients with severe persistent asthma for a treatment period of 12 weeks versus budesonide 2mg via nebulizer BID. The steady-state plasma pharmacokinetics of fluticasone propionate inhalation solution will also be assessed.
Phase:
Phase 3
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Budesonide
Fluticasone
Pharmaceutical Solutions
Xhance